Pfizer Limited reported a solid set of results for the third quarter, with profitability improving sharply alongside strong topline growth.
Net profit for the quarter rose 11.1% year-on-year to ₹141.8 crore, compared with ₹127.6 crore in the same period last year. Revenue grew a robust 19.9% YoY to ₹645 crore, up from ₹538 crore, indicating healthy demand across key therapy areas.
Operating performance strengthened materially during the quarter. EBITDA surged 55.8% YoY to ₹228.3 crore, compared with ₹146.5 crore a year earlier. This led to a significant improvement in operating margins, which expanded to 35.4% from 27.2% in the corresponding quarter last year, reflecting operating leverage and improved cost efficiencies.
Ahead of the earnings announcement, shares of Pfizer Limited closed at ₹4,770, up ₹179.70 or 3.91% on the NSE.
Also Read: Jubilant Agri posts steady Q3 show as sales and operating profits grow, net profit inches up
Pfizer Limited is a leading pharmaceutical company in India, engaged in the manufacturing, marketing, trading and export of pharmaceutical products across therapeutic segments including vaccines, anti-infectives, pain management and chronic therapies.
